The Impact of Cannabidiol (CBD) on Lipid Absorption and Lymphatic Transport in Rats

Background: Cannabidiol (CBD) exerts diverse metabolic effects, yet its influence on intestinal lipid metabolism remains unclear. Methods: In this study, we investigated whether short-term (one-week) CBD treatment affects lipid absorption and transport through the lymphatic system using a validated lymph fistula model. Results: CBD treatment significantly enhanced the transport of radiolabeled triglycerides through the lymphatic system. This effect appeared specific, as CBD did not substantially alter cholesterol output in the lymph. Chemical assays indicated that CBD treatment did not significantly alter total triglycerides, cholesterol, phospholipids, or non-esterified fatty acid levels in the lymph. However, it significantly enhanced the lymphatic output of apolipoprotein A4 (ApoA4) and apolipoprotein A1 (ApoA1). Additionally, gene expression analysis revealed a downregulation of vascular endothelial growth factor receptor 1 (Flt1) in the small intestine, leading to increased lymphatic lacteal permeability and altered lipid transport dynamics. Conclusions: These findings indicate that short-term CBD treatment modulates lymphatic lipid composition and apolipoprotein secretion by regulating lymphatic lacteal function, thereby influencing lipid transport and metabolism. This study provides novel insights into CBD's role in facilitating TG-rich lipoprotein transport via the lymphatic system, highlighting its potential therapeutic applications in lipid-related disorders.